There were 88 press releases posted in the last 24 hours and 218,942 in the last 365 days.

CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

/EIN News/ -- BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the third quarter and nine months ended September 30, 2019 and provided an update on recent business developments.

Recent Corporate Highlights:

  • Positive responses received from the FDA regarding the Company’s pre-New Drug Application, or pre-NDA, meeting questions relating to the preparation of the NDA.  The FDA agreed that Neutrolin is eligible for priority review, setting a review period goal of 6 months rather than the standard review period of 10 months.  The FDA also agreed that the Neutrolin NDA submission is eligible for rolling review and that the Company’s proposed submission plan is reasonable.  The FDA further agreed that it is appropriate to submit a request for approval of Neutrolin under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD Pathway) at the time of the NDA submission. 
  • The Company completed its interaction with the FDA related to the chemistry, manufacturing and controls (CMC) package that will be required to support Neutrolin’s NDA. The FDA was supportive of Neutrolin’s proposed manufacturing program, including the manufacture of the active pharmaceutical ingredients (APIs), the container closure and testing, and indicated that it will conduct a thorough review of all of the CMC information as well as assess the commercial readiness of the various manufacturing facilities at the time of the NDA filing.  No further CMC meetings with the FDA are planned prior to the NDA submission.
  • The Company believes it is on schedule for NDA submission and potential for approval during the second half of 2020.
  • CorMedix is developing the regulatory pathways aimed at additional indications for use in catheters for oncology patients and for patients requiring total parenteral nutrition (TPN).  The Company is first focused on securing the indication for use in hemodialysis patients utilizing data from LOCK-IT-100, because it believes this strategy will provide greater opportunity for generating the clinical data needed for additional indications for use. 

Khoso Baluch, CorMedix CEO commented, “We are delighted to have completed the CMC and pre-NDA meetings with the FDA.  I believe we have entered the home stretch towards our goal of getting Neutrolin approved in the U.S. in the second half of 2020.  We are now able to focus our full attention on submitting the new drug application as quickly as possible.  Over the next several months, we expect to build manufacturing, marketing and medical affairs capabilities in anticipation of commercial launch either alone or with a partner.   This is an exciting time for the Company and for the staff who have worked so hard to get us where we are today.”

Third Quarter and Nine Month 2019 Financial Highlights

For the third quarter of 2019, CorMedix recorded a net loss attributable to common shareholders of $32.4 million, or $1.35 per share, compared with a net loss of $10.2 million, or $0.54 per share, in the third quarter 2018, an increase of $22.2 million. The increase in net loss in the third quarter 2019 compared with the third quarter of 2018 was driven primarily by the deemed dividends recognized as a result of the exchange agreement and modification of certain warrants completed in September 2019 totaling $27.1 million.  The net loss for the third quarter of 2019 before recognition of the deemed dividends was $5.3 million. 

For the nine months ended September 30, 2019, CorMedix recorded a net loss attributable to common shareholders of $38.2 million, or $1.62 per share, compared with a net loss of $29.0 million, or $1.73 per share, in the first nine months of 2018, an increase of $9.2 million. The increase in net loss in the first nine months of 2019 compared with the first nine months of 2018 was driven primarily by the deemed dividends recognized as a result of the exchange agreement and modification of certain warrants totaling $27.1 million during the first nine months of 2019, partially offset by decreased clinical trial expense of $16.2 million.  The net loss before recognition of the deemed dividends during the first nine months of 2019 was $11.1 million. 

Operating expenses during the third quarter of 2019 were $5.2 million, compared with $10.3 million in the third quarter of 2018, a decrease of approximately 50%. This decrease was due primarily to a $5.8 million, or 70%, decrease in R&D expense, while SG&A expense increased by 31%.   Operating expenses during the nine-month period ended September 30, 2019 amounted to $15.6 million compared with $29.0 million during the comparable period in 2018, a reduction of $13.4 million, or 46%, due to a 64% reduction in R&D expense partially offset by a 23% increase in SG&A. 

In September 2019, the Company closed an Exchange Agreement with funds managed by Elliott Management Corporation, its largest investor.  In connection with the Exchange Agreement, Elliott agreed to make a cash payment of $2.0 million and to exchange all of its outstanding warrants, 10% Senior Secured Convertible Notes (the principal and accrued interest of which would have amounted to a repayment obligation of approximately $10.1 million or been convertible into approximately 1.35 million shares if held to maturity), and Series C-2, Series D and Series F Convertible Preferred Stock for new Series G Convertible Preferred Stock.  The new Series G Convertible Preferred Stock is convertible into an aggregate of 5,560,138 shares of Common Stock, subject to a claw back of up to 139,769 shares of Common Stock, depending upon the occurrence of certain stock price-related conditions.  With the completion of this exchange, the Company raised additional capital, became debt-free and substantially reduced the amount of outstanding warrants as well as its classes of outstanding preferred stock. 

Also in September 2019, as part of its continuing efforts to simplify its capital structure, the Company agreed to reduce the exercise price on 1.2 million of its Series B Warrants expiring August 2022 from the current exercise price of $5.25 to $4.00 in return for their immediate exercise, which generated cash of $4.9 million.

The Exchange Agreement and warrant strike price reductions along with exercises of warrants held by other investors during the 2nd quarter of 2019 resulted in the Company receiving gross proceeds of approximately $10 million during the quarter and reducing its warrant overhang by approximately 2.9 million shares.  Warrants to purchase approximately 345,000 shares are currently outstanding.
Total cash on hand and short-term investments as of September 30, 2019 amounted to $32.4 million, excluding restricted cash of $0.2 million.  The Company believes that, based on the Company’s cash resources at September 30, 2019, it has sufficient resources to fund operations into 2021, including the submission of the NDA for Neutrolin and initial preparations for commercial launch.

Conference Call Information

The management team of CorMedix will host a conference call and webcast today, November 14, 2019, at 4:30 PM Eastern Time, to discuss recent corporate developments and financial results. Call details and dial-in information is as follows:

Domestic: 877-423-9813
International: 201-689-8573
Passcode 13695966

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis. Such infections have significant treatment costs and lead to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provide the potential for priority review of a marketing application by FDA and allow for a total of ten years of market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels.  The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.  For more information, visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the results of our discussions with the FDA regarding the Neutrolin development path, including whether a second Phase 3 clinical trial for Neutrolin will be required; the resources needed to complete the information required to submit a new drug application for Neutrolin to the FDA; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on current, planned or future research, including the continued development of Neutrolin and research for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel to staff our operations appropriately. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors




    For the Three Months Ended
September 30,
  For the Nine Months Ended
September 30,
    2019     2018     2019     2018  
Net sales $ 59,530   $ 372,514   $ 258,488   $ 403,274  
Cost of sales   (79,026 )   (312,434 )   (327,109 )   (374,672 )
Gross profit (loss)   (19,496 )   60,080     (68,621 )   28,602  
Operating Expenses:                
Research and development   (2,520,992 )   (8,289,094 )   (8,375,896 )   (23,169,750 )
Selling, general and administrative   (2,631,027 )   (2,012,439 )   (7,187,535 )   (5,861,279 )
Total Operating Expenses   (5,152,019 )   (10,301,533 )   (15,563,431 )   (29,031,029 )
Loss From Operations   (5,171,515 )   (10,241,453 )   (15,632,052 )   (29,002,427 )
Other Income (Expense)   (93,332 )   5,334     (557,615 )   24,280  
Net Loss Before Income Taxes   (5,264,847 )   (10,236,119 )   (16,189,667 )   (28,978,147 )
Tax Benefit   -     -     5,060,778     -  
Net Loss   (5,264,847 )   (10,236,119 )   (11,128,889     (28,978,147 )
Total other comprehensive income (loss)   (2,339 )   (6,405 )   5,479     (7,435 )
Comprehensive Loss $ (5,267,186 ) $ (10,242,524 ) $ (11,123,410 ) $ (28,985,582 )
Net Loss $ (5,264,847 ) $ (10,236,119 ) $ (11,128,889 ) $ (28,978,147 )
Deemed dividend as a result of warrant modification   (369,500 )   -     (369,500 )   -  
Deemed dividend as a result of exchange of convertible note, Series C-2, D and F preferred stock, related party   (26,733,098 )   -     (26,733,098 )   -  
Net Loss Attributable to Common Shareholders $ (32,367,445 ) $ (10,236,119 ) $ (38,231,487 ) $ (28,978,147 )
Net Loss Per Common Share – Basic and Diluted $ (1.35 ) $ (0.54 ) $ (1.62 ) $ (1.73 )
Weighted Average Common Shares Outstanding  – Basic and Diluted   24,015,927     18,831,317     23,642,033     16,780,833  


     September 30,    December 31,
    2019    2018 
Cash, cash equivalents and restricted cash $   20,315,346   $   17,795,323  
Short-term investments $ 12,294,290   $ -  
Total Assets $   33,717,463   $ 18,825,914  
Total Liabilities $ 5,009,688   $ 13,891,658  
Accumulated deficit $  (190,116,987 ) $  (178,988,098 )
Total Stockholders’ Equity $  28,707,775   $  4,934,256  


   Nine Month Periods Ended September 30,
  2019   2018
Net loss $   (11,128,889 )   $   (28,978,147 )
Net cash used in operating activities    (11,167,318 )      (16,500,414 )
Net cash (used in) provided by investing activities   (12,316,718 )      1,555,305  
Proceeds from sale of common stock from at-the-market program    15,234,529        11,012,647  
Proceeds from the exercise of warrants   8,658,233        -  
Proceeds from the exchange agreement   2,000,000       -  
Proceeds from exercise of stock options   117,529       -  
Net cash provided by financing activities   26,010,291       11,012,647  

  2,520,023        (3,935,861 )

Primary Logo